tris DBA palladium (Tris DBA) / Emory University School of Medicine - LARVOL DELTA

A Versatile System of Solvent, Catalyst, and Ligand for Challenging Biphenyl Synthesis Through Suzuki-Miyaura Reactions. (PubMed, Chemistry) - "The system consists of N-methylpyrrolidone as solvent, tris(dibenzylidenaceton)dipalladium(0) as catalyst, CuI as cocatalyst, and Davephos as ligand. This combination yields little or no Ullmann product, and the desired cross-coupling product is in moderate to excellent yields."

Journal

Precise Synthesis of Ester-Functionalized Cyclo[6]- and Cyclo[7]furans. (PubMed, J Org Chem) - "We demonstrate that the combination of hexyl 2-bromo-5-(boronic acid pinacol ester)furan-3-carboxylate with tris(dibenzylideneacetone)dipalladium(0), tri-tert-butylphosphonium tetrafluoroborate and cesium fluoride leads to cyclo[6]- and cyclo[7]furan esters in 45% yield (28% and 17%, respectively)...The hexyl-substituted cyclo[n]furan esters (n = 6 and 7) are separable via column chromatography. The unique optical and electronic features for each cycle can be partially explained by the size difference for the two systems, as well as the increased conformational flexibility for the larger, ester-functionalized cyclo[7]furan."

Journal

Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway. (PubMed, Cancers (Basel)) - "Tris DBA significantly inhibited tumor growth in xenograft MM and orthotopic HCC preclinical mice models with a reduction in the expression of various prosurvival biomarkers in MM tumor tissues without displaying significant toxicity. Overall, Tris DBA functions as a good inhibitor of STAT3 signaling in preclinical HCC and MM models."

Journal • Preclinical • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Multiple Myeloma • Oncology • Solid Tumor • IL6 • JAK1 • JAK2

Differences in the Performance of Allyl Based Palladium Precatalysts for Suzuki-Miyaura Reactions. (PubMed, Adv Synth Catal) - "Additionally, we compare the performance of in situ generated precatalysts with commonly used palladium sources such as tris(dibenzylideneacetone)dipalladium(0) (Pddba), bis(acetonitrile)dichloropalladium(II) (Pd(CHCN)Cl), and palladium acetate. Our results provide information about which precatalyst to use under different conditions."

Journal

Tris DBA Ameliorates Accelerated and Severe Lupus Nephritis in Mice by Activating Regulatory T Cells and Autophagy and Inhibiting the NLRP3 Inflammasome. (PubMed, J Immunol) - "Tris DBA improved ASLN in mice through immunoregulation by blunting the MAPK (ERK, JNK)-mediated priming signal of the NLRP3 inflammasome and by regulating the autophagy/NLRP3 inflammasome axis. These results suggest that the pure compound may be a drug candidate for treating the accelerated and deteriorated type of lupus nephritis."

Journal • Preclinical • Complement-mediated Rare Disorders • Gastrointestinal Cancer • Glomerulonephritis • Hematological Malignancies • Hepatology • Immunology • Inflammation • Inflammatory Arthritis • Leukemia • Lupus • Lupus Nephritis • Multiple Myeloma • Nephrology • Oncology • Pancreatic Cancer • Renal Disease

Tris DBA ameliorates IgA nephropathy by blunting the activating signal of NLRP3 inflammasome through SIRT1- and SIRT3-mediated autophagy induction. (PubMed, J Cell Mol Med) - "In conclusion, Tris DBA effectively ameliorated the mouse IgAN model and targeted signalling pathways downstream of ICs-mediated interaction, which is a novel immunomodulatory strategy. Further development of Tris DBA as a therapeutic candidate for IgAN is warranted."

Journal • Gastrointestinal Cancer • Glomerulonephritis • Hematological Malignancies • Hepatology • Immune Modulation • Immunology • Inflammation • Leukemia • Multiple Myeloma • Oncology • Pancreatic Cancer • Renal Disease • Solid Tumor • MAPK8 • SIRT1

Palladium based nanoparticles for the treatment of advanced melanoma. (PubMed, Sci Rep) - "Surprisingly, the HANP containing IGF1R antibody was less effective than particles without antibody, possibly due to steric hindrance of IGF1R and CD44 binding. Tris DBA-Pd nanoparticles are an effective therapy for CD44-positive tumors like melanoma, and further development of these nanoparticles should be pursued."

Journal • Melanoma • Oncology • Solid Tumor